SCHEMBL30766002

SCHEMBL30766002

C[C@@H](Nc1cnc(N2CCCC2)n(CC(=O)OC(C)(C)C)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.37
MAPK1 P28482 2/20 0.37
HTT P42858 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
BACE1 P56817 1/20 0.34
LMNA P02545 4/20 0.34
MCHR1 Q99705 1/20 0.34
ALK Q9UM73 1/20 0.33
PIK3CA P42336 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KMT2A Q03164 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558461 0.93 BACE1 (0.43) HTTBACE1LMNAALK
SCHEMBL30765863 0.89 GAA (0.38) USP2MAPK1HTTPOLBGAA
SCHEMBL31558557 0.88 POLB (0.37) USP2MAPK1HTTPOLBGAA
SCHEMBL30765755 0.88 BACE1 (0.37) USP2GAAKDM4EALDH1A1BACE1
SCHEMBL30765957 0.87 ALDH1A1 (0.38) USP2POLBKDM4EALDH1A1JAK2
SCHEMBL30766008 0.86 BACE1 (0.43) HTTBACE1LMNAALKPIK3CA
SCHEMBL30765899 0.86 CYP8B1 (0.34) BACE1PIK3CA
SCHEMBL30765991 0.86 ELANE (0.42) KDM4EALDH1A1JAK2JAK1JAK3
SCHEMBL30765995 0.86 ALDH1A1 (0.37) USP2KDM4EALDH1A1JAK2JAK1
SCHEMBL30765941 0.86 ALDH1A1 (0.37) USP2MAPK1GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed